Table 2:

Engraftment patterns in haplo-dCBT recipients (n = 77 evaluable patients).

Engraftment Group	Engraftment Median (range)
Group 1: CB engraftment with optimal (early and sustained) haplo-derived myeloid bridge (n = 34, 44%)	Neutrophils: 12 days (10–14) Platelets: 19 days (14–41) in 32 patients
Group 2: CB engraftment with transient haplo-derived myeloid bridge and second nadir (n = 20, 26%)	Neutrophils: 12 (11–18) and 26.5 days (20–46) [duration of 2nd nadir: 8.5 days (4–19)] Platelets: 43.5 days (range 14–67) in 20 patients
Group 3: CB engraftment with no haplo-derived myeloid bridge (n = 21, 27%)	Neutrophils: 25 days (15–33) Platelets: 45.5 days (range 37–62) in 16 patients
Group 4: CB graft failure (n = 2, 3%)	Patient 1: Failure of both haplo-identical donor and CB engraftment in the presence of DSA**. Patient 2: Transient haplo-CD34+ derived myeloid bridge (day 12), followed by CB graft failure in the setting of low infused viable CD34+ cell dose of both CB units.

^*1 patient not evaluable for engraftment due to early TRM on day 14.

^**Of the 7 patients with DSA against the CB graft, one patient had graft failure. The remaining 6 patients had sustained CB engraftment (4 Group 1, 2 Group 3).